The article examines the role of Shreya Life Sciences, an Indian pharmaceutical company, as a major conduit in the supply chain of advanced technology to Russia. Despite international sanctions intended to restrict Russia’s access to high-tech components with potential military applications, Shreya has managed to legally export Nvidia-powered AI servers valued at over $300 million to Russia. Through intermediaries, primarily from India and Malaysia, Shreya has become a notable example of how companies can maneuver within regulatory frameworks, raising concerns among Western governments about India’s growing role in supplying dual-use technology. The piece highlights the complexities of global trade, especially as geopolitical alliances shift amidst the Russia-Ukraine conflict, underscoring the challenges in enforcing sanctions on critical technologies.
1 comment
**Submission Statement**
The article examines the role of Shreya Life Sciences, an Indian pharmaceutical company, as a major conduit in the supply chain of advanced technology to Russia. Despite international sanctions intended to restrict Russia’s access to high-tech components with potential military applications, Shreya has managed to legally export Nvidia-powered AI servers valued at over $300 million to Russia. Through intermediaries, primarily from India and Malaysia, Shreya has become a notable example of how companies can maneuver within regulatory frameworks, raising concerns among Western governments about India’s growing role in supplying dual-use technology. The piece highlights the complexities of global trade, especially as geopolitical alliances shift amidst the Russia-Ukraine conflict, underscoring the challenges in enforcing sanctions on critical technologies.
Comments are closed.